Psychiatry · Johnson City, TN
NPI
1356322515
Since 2005
Specialty
Psychiatry
Code 2084P0800X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2306 Knob Creek Rd Ste 104
Johnson City, TN, 37604
Phone (423) 794-7490
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$404K
1,584 prescriptions
Company payments, 2025
$769K
From 11 companies
Medicare prescription drug claims, 2024
In 2024, the drug Brian R Bonfardin prescribed most often to Medicare patients was Clonazepam, with 112 prescriptions and refills. In total Brian R Bonfardin wrote 1,584 Medicare prescriptions that cost $404K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-12.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Clonazepam Generic | 112 | 112 | 14 | $923 |
| Aripiprazole Generic | 90 | 103 | 13 | $4,140 |
| Alprazolam Generic | 85 | 85 | Under 11 | $686 |
| Duloxetine Hcl Generic | 70 | 112 | Under 11 | $1,420 |
| Fanapt Iloperidone | 66 | 67 | Under 11 | $189K |
| Diazepam Generic | 63 | 63 | Under 11 | $364 |
| Sertraline Hcl Generic | 57 | 107 | 11 | $612 |
| Trazodone Hcl Generic | 54 | 102 | 13 | $895 |
| Lorazepam Generic | 49 | 49 | 12 | $187 |
| Gabapentin Generic | 46 | 46 | Under 11 | $426 |
| Buspirone Hcl Generic | 40 | 69 | Under 11 | $894 |
| Oxcarbazepine Generic | 37 | 57 | Under 11 | $3,046 |
| Fluoxetine Hcl Generic | 37 | 65 | Under 11 | $366 |
| Clonidine Hcl Generic | 36 | 42 | Under 11 | $235 |
| Zolpidem Tartrate Generic | 34 | 34 | Under 11 | $258 |
Brand drugs: 204 claims; generic drugs: 1,380 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Brian R Bonfardin $769K ($769K in general payments such as food, travel and fees) from 11 companies. The largest payer was Vanda Pharmaceuticals Inc. with $227K.
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. VNDA | 285 | $227K |
| Abbvie Inc. ABBV | 142 | $135K |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 96 | $111K |
| Axsome Therapeutics, Inc. AXSM | 90 | $102K |
| Otsuka America Pharmaceutical, Inc. 4578.T | 93 | $92K |
| Alkermes, Inc. ALKS | 83 | $64K |
| E.R. Squibb & Sons, L.L.C. BMY | 37 | $28K |
| Supernus Pharmaceuticals, Inc. SUPN | 8 | $9,247 |
| Lundbeck LLC | 2 | $28.43 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $19.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.